Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques

Virology

Volumn 277, Issue 2, 2000, Pages 306-315

  Smith, Marilyn S ^a,b   Foresman, Larry ^a,f   Lopez, Grisel J ^a,b   Tsay, John ^a   Wodarz, Dominik ^c   Lifson, Jeffrey D ^d   Page, Angelina ^a   Wang, Chunyang ^a,g   Li, Zhuang ^a   Adany, Istvan ^a   Buch, S ^a,b   Bischofberger, Norbert ^e   Narayan, Opendra ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR ADVANCED STUDY   (United States)

^d SAIC FREDERICK INC   (United States)

^e GILEAD SCIENCES   (United States)

^f MONSANTO COMPANY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Macaque; PMPA; SHIV(KU2); Viral dynamics

Indexed keywords

(2 PHOSPHONOMETHOXYPROPYL)ADENINE; ANTIRETROVIRUS AGENT; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCULATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DYNAMICS; INOCULATION; LYMPH NODE; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIREMIA; VIROGENESIS; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0034715789     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0609     Document Type: Article

References (38)

1. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound
2. Neuropathogenesis of chimeric simian-human immunodeficiency virus infection in rhesus macaques
3. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
4. In search of a selective antiviral chemotherapy
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
6. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques
7. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
8. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
9. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
10. Intracerebral infusion of TNF-alpha and IL-6 failed to activate latent SIV infection in the brain of macaques inoculated with macrophage-tropic neuro-adapted SIVmac
11. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques
12. Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques
13. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques
14. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
15. Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: Effects of splenectomy on virus burden
16. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
17. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection
18. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life span, and viral generation time
19. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8
20. Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immuno-deficiency virus-positive patients and correlation with serological measurements
21. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3'-azido-3'-deoxythymidine
22. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy
23. Plasma SIV RNA viral load by real time quantification of product generation in RT PCR
24. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIV(mne) infection depends critically on timing of initiation and duration of treatment
25. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques
26. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
27. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection
28. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques
29. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA
30. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
31. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques
32. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type2-infected macaques
33. Viral dynamics in human immunodeficiency virus type 1 infection
34. Specific therapy regimes could lead to long-term immunological control of HIV
35. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
36. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia
37. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
38. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy